Taysha Therapeutics has initiated dosing in its pivotal trial for TSHA-102, a gene therapy targeting Rett syndrome, with plans to complete dosing by Q2 2026. The FDA has provided written alignment on a potential BLA strategy, highlighting the significant unmet need for the estimated 15,000 to 20,000 patients affected by this condition.